CITIUS ONCOLOGY, INC. (CTOR) Form 8-K — Aug 12, 2026

$CTORForm 8-KItems 5.02, 9.01Filed Aug 12, 2026, 8:30 AM ET0001213900-26-088068Original filing

Citius Oncology (Nasdaq: CTOR) announced on August 12, 2026 that its Board unanimously appointed Jonathan Peri, Ph.D., J.D. as an additional independent director, expanding the Board to nine members effective August 10, 2026. Dr. Peri will serve as a Class I director until the 2028 annual meeting, and the Board remains majority independent under SEC and Nasdaq rules.

Key figures

Director age: 52
Ctcl market estimate usd: 400000000
Board size after expansion: 9

Price after filing

1 day: +1.9%7 days: -7.3%30 days: +13.1%

Close on the filing date to close N calendar days later (from $0.81). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.